NASDAQ:LKFT Lakefront Biotherapeutics American Depositary Shares Q2 2026 Earnings Report $29.84 +0.46 (+1.57%) As of 04:00 PM Eastern ProfileEarnings HistoryForecast Lakefront Biotherapeutics American Depositary Shares EPS ResultsActual EPS$0.04Consensus EPS -$0.97Beat/MissBeat by +$1.01One Year Ago EPSN/ALakefront Biotherapeutics American Depositary Shares Revenue ResultsActual Revenue$15.47 millionExpected Revenue$7.29 millionBeat/MissBeat by +$8.18 millionYoY Revenue GrowthN/ALakefront Biotherapeutics American Depositary Shares Announcement DetailsQuarterQ2 2026Date8/10/2026TimeAfter Market ClosesConference Call DateTuesday, August 11, 2026Conference Call Time8:00AM ETConference Call ResourcesPress ReleaseInterim ReportEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress ReleaseInterim report Lakefront Biotherapeutics American Depositary Shares Earnings HeadlinesContrasting Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) and X4 Pharmaceuticals (NASDAQ:XFOR)September 28 at 4:44 AM | americanbankingnews.comLakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Raised to "Outperform" at Royal Bank Of CanadaSeptember 25 at 2:12 AM | americanbankingnews.comMILLIONAIRE MASTERCLASS INVITE: AltucherJames Altucher says Elon Musk is preparing an unprecedented project set to surface on December 8th. Altucher is hosting a free masterclass revealing what he says is locked inside a sealed briefcase detailing Musk's plans. Attendees who join early can also access a $1,000 bonus offer included with the presentation.September 28 at 1:00 AM | Paradigm Press (Ad)Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Shares Gap Up Following Analyst UpgradeSeptember 25 at 1:21 AM | americanbankingnews.comLakefront Biotherapeutics Stock Rises 4% After Share Repurchase UpdateSeptember 24, 2026 | rttnews.comLakefront Biotherapeutics' Gamgertamig Has Meaningful Opportunity in Rare Autoimmune Diseases, RBC SaysSeptember 23, 2026 | marketscreener.comMSee More Lakefront Biotherapeutics American Depositary Shares Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Lakefront Biotherapeutics American Depositary Shares? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lakefront Biotherapeutics American Depositary Shares and other key companies, straight to your email. Email Address About Lakefront Biotherapeutics American Depositary SharesLakefront is a clinical-stage biotechnology company developing therapies in immunology and inflammation. Its clinical-stage portfolio includes lead asset gamgertamig, a BCMAxCD3 T-cell engager being developed for the treatment of autoimmune diseases. The company identifies, acquires, and advances therapeutic assets through business development and clinical development activities. Lakefront evaluates opportunities for portfolio expansion based on their scientific, clinical, and commercial potential. Lakefront focuses on developing medicines for diseases with unmet medical needs and advancing its product candidates through clinical development.View Lakefront Biotherapeutics American Depositary Shares ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Brewing Trouble? Starbucks Spills the Beans on 250 Store ClosuresMarketBeat Week in Review – 09/21 - 09/25Analyst Rating Boosts May Signal More Upside for These 3 Stocks3 Stocks Under the Microscope After Large Insider Sales3 Healthcare Stocks Showing Why the Sector Still Has Momentum2 Cybersecurity Stocks Breaking Out as AI Continues to Be a TailwindFertilizer Prices Keep Climbing: 3 Stocks Still Trading at a Discount Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
